Table 6 Medical decision making on advanced treatment

adenocarcinoma with solitary liver metastases

Systemic chemotherpy

0.443

Systemic chemotherpy

4

3.96

7

4.35

5

5.21

Liver lesion resection

8

7.92

16

9.94

5

5.21

TACE

10

9.90

21

13.04

15

15.63

Liver lesion resection + systemic chemotherpy

79

78.22

117

72.67

68

70.83

Other

0

0

0

0

3

3.13

adenocarcinoma with large quantity of ascites

Systemic chemotherpy

0.210

Systemic chemotherapy

3

2.97

2

1.24

2

2.08

intraperitoneal chemotherapy(IP)

4

3.96

6

3.73

5

5.21

Systemic chemotherapy+IP

94

93.07

153

95.03

89

92.71

0.254

Other

0

0

0

0

0

0

lungs metastases

Paclitaxel or docetaxel based regime or ECF(EPI+DDP+5FU)

0.070

CF(DDP+5FU)

2

1.98

3

1.86

1

1.04

ECF(EPI+DDP+5FU)

17

16.83

23

14.29

9

9.38

Fluoropyrimidine(5Fu or Capecitabine)

13

12.87

12

7.45

14

14.58

Oxaliplatin based regimen

33

32.67

51

31.68

25

26.04

Irinotecan based regimen

9

8.91

22

13.66

15

15.63

Paclitaxel or docetaxel based regime

25

24.75

46

28.57

29

30.21

Combination of above or other

2

1.98

4

2.48

3

3.13

lungs metastases, failure after ECF(EPI+DDP+5FU)

Change regimen and continue chemotherapy

Change regimen and continue chemotherapy

101

100

156

96.89

83

86.46

0.137

Best supportive care

0

0

2

1.24

9

9.38

Other

0

0

3

1.86

4

4.17

lungs metastases, failure after both ECF and Paclitaxel+DDP

Change regimen and continue chemotherapy

0.351

Change regimen and continue chemotherapy

86

85.15

122

75.78

60

62.50

Best supportive care

13

12.87

35

21.74

31

32.29

Other

2

1.98

4

2.48

5

5.21

lungs metastases, failure after both ECF and Paclitaxel+DDP, PS 3

Best supportive care

0.222

Change regimen and continue chemotherapy

18

17.82

15

9.32

9

9.38

Best supportive care

79

78.22

136

84.47

81

84.38

Other

4

3.96

10

6.21

6

6.25